Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma
N/A
N/A
Both
HIV, Lymphoma
Trial Information
Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma
The study team will take two or three tubes of blood on three occasions during the course of
chemotherapy. The total amount of blood required for this research project is 64mL
(approximately 4 tablespoons).
This will allow better understanding of the changes that take place in the blood and the HIV
virus itself. It is hoped that this will provide new insights that may aid the understanding
and treatment of HIV patients with lymphoma.
Inclusion Criteria:
- The ability to understand and sign a written informed consent form, prior to
participation in any screening procedure and must be willing to comply with all study
requirements.
- Documented HIV-1 infection.
- Diagnosis of lymphoma (with the exclusion of the five subjects that will be
controls).
- On cART or about to start cART as part of clinical routine care before the initiation
of chemotherapy.
Exclusion Criteria:
- Receiving anti-tuberculosis treatment.
Type of Study:
Observational
Study Design:
Observational Model: Case Control
Outcome Measure:
Development of multi-drug resistance (in terms of expression of transmembrane transporters and their transcriptional regulators) in HIV-infected patients with lymphoma.
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Marta Boffito, Dr
Investigator Role:
Principal Investigator
Investigator Affiliation:
St Stephen's AIDS Trust
Authority:
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study ID:
SSAT 042
NCT ID:
NCT01330342
Start Date:
May 2011
Completion Date:
May 2014
Related Keywords:
- HIV
- Lymphoma
- Lymphoma
Name | Location |
|---|
